KVISTGAARD
Denmark
130
2022-03-24
117
2023-08-15
These are the the leading inventors for applications assigned to BAVARIAN NORDIC A/S:
BAVARIAN NORDIC A/S based in KVISTGAARD, DK has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
Poxvirus vectors encoding HIV antigens, and methods of use thereof
#2 | 2022-03-24 ✅ Patent 11,918,639 granted on 2024-03-05Methods and compositions for inducing protective immunity against filovirus infection
#3 | 2020-10-01 ✅ Patent 11,273,211 granted on 2022-03-15Combination therapy for treating cancer with an intravenous administration of a recombinant MVA and an antibody
#4 | 2020-08-27 ✅ Patent 11,338,030 granted on 2022-05-24Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens
#5 | 2020-06-04 ✅ Patent 10,946,089 granted on 2021-03-16Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#6 | 2020-05-07 ✅ Patent 11,229,693 granted on 2022-01-25Poxvirus vectors encoding HIV antigens, and methods of use thereof
#7 | 2020-04-02 ✅ Patent 11,173,204 granted on 2021-11-16MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
#8 | 2020-02-27 ✅ Patent 11,052,139 granted on 2021-07-06Compositions and methods for enhancing the stability of transgenes in poxviruses
#9 | 2020-02-06 ✅ Patent 11,173,201 granted on 2021-11-16Methods and compositions for inducing protective immunity against filovirus infection
#10 | 2019-07-25 ✅ Patent 10,925,956 granted on 2021-02-23Methods and compositions for inducing protective immunity against a marburg virus infection
#11 | 2019-05-16 ✅ Patent 10,517,944 granted on 2019-12-31Therapeutic HPV vaccine combinations
#12 | 2019-04-25 ✅ Patent 10,532,094 granted on 2020-01-14Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#13 | 2019-02-21 ✅ Patent 11,225,673 granted on 2022-01-18Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity
#14 | 2019-02-07 ✅ Patent 10,881,725 granted on 2021-01-05Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine
#15 | 2018-08-02 ✅ Patent 11,753,652 granted on 2023-09-12Cassette encoding a FPV/brachyury fusion protein
#16 | 2018-07-05 ✅ Patent 11,103,570 granted on 2021-08-31Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine
#17 | 2018-04-26 ✅ Patent 11,028,130 granted on 2021-06-08PR13.5 promoter for robust T-cell and antibody responses
#18 | 2017-11-30 ✅ Patent 10,561,722 granted on 2020-02-18Methods and compositions for enhancing immune responses
#19 | 2017-11-16 ✅ Patent 10,124,058 granted on 2018-11-13Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RSV) vaccine
#20 | 2017-10-26 ✅ Patent 10,576,141 granted on 2020-03-03Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use
#21 | 2017-10-12 ✅ Patent 10,512,684 granted on 2019-12-24Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin
#22 | 2017-10-12 ✅ Patent 10,561,721 granted on 2020-02-18Methods and compositions for inducing protective immunity against filovirus infection
#23 | 2017-09-21Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
#24 | 2017-07-27 ✅ Patent 10,072,274 granted on 2018-09-11Vector comprising multiple homologous nucleotide sequences
#25 | 2017-05-18AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR (TLR) 13
#26 | 2017-05-11 ✅ Patent 10,653,766 granted on 2020-05-19Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus
#27 | 2017-04-20Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
#28 | 2017-03-23RECOMBINANT POXVIRUS VECTOR COMPRISING TETANUS TOXIN FRAGMENT C
#29 | 2017-02-16 ✅ Patent 9,717,787 granted on 2017-08-01Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#30 | 2016-12-29COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORS
#31 | 2016-09-22Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
#32 | 2016-02-04 ✅ Patent 9,707,291 granted on 2017-07-18Single high dose of MVA induces a protective immune response in neonates and infants
#33 | 2016-01-21 ✅ Patent 9,540,660 granted on 2017-01-10Vector comprising multiple homologous nucleotide sequences
#34 | 2015-10-22 ✅ Patent 9,828,414 granted on 2017-11-28Pr13.5 promoter for robust T-cell and antibody responses
#35 | 2015-07-30 ✅ Patent 9,480,738 granted on 2016-11-01Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
#36 | 2015-07-23 ✅ Patent 10,973,892 granted on 2021-04-13Methods and compositions for enhancing vaccine immune responses
#37 | 2015-06-25 ✅ Patent 10,111,946 granted on 2018-10-30Poxviral vectors for low antibody response after a first priming immunization
#38 | 2014-12-25 ✅ Patent 9,556,439 granted on 2017-01-31Agonists and antagonists of toll-like receptor (TLR) 13
#39 | 2014-11-20PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION
#40 | 2014-11-20 ✅ Patent 9,265,823 granted on 2016-02-23Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
#41 | 2014-10-30 ✅ Patent 9,463,238 granted on 2016-10-11Recombinant poxvirus vector comprising tetanus toxin fragment C
#42 | 2014-04-24 ✅ Patent 9,163,237 granted on 2015-10-20Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
#43 | 2013-10-31 ✅ Patent 9,109,201 granted on 2015-08-18Purification of vaccinia viruses using hydrophobic interaction chromatography
#44 | 2013-09-19 ✅ Patent 8,741,308 granted on 2014-06-03Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#45 | 2013-09-05 ✅ Patent 8,883,168 granted on 2014-11-11Modulation of immune responses by the poxviral K4 protein
#46 | 2013-08-22 ✅ Patent 8,961,998 granted on 2015-02-24Immediate protection against pathogens via MVA
#47 | 2013-07-18 ✅ Patent 10,087,423 granted on 2018-10-02Method for harvesting expression products
#48 | 2013-07-18 ✅ Patent 9,173,933 granted on 2015-11-03Recombinant modified vaccinia virus Ankara influenza vaccine
#49 | 2013-04-11 ✅ Patent 8,673,318 granted on 2014-03-18Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
#50 | 2012-12-27MODIFIED VACCINIA ANKARA VIRUS VARIANT
#51 | 2012-12-06 ✅ Patent 8,859,257 granted on 2014-10-14Vaccinia virus mutants containing the major genomic deletions of MVA
#52 | 2012-11-01 ✅ Patent 8,470,598 granted on 2013-06-25Modified Vaccinia Ankara virus variant and cultivation method
#53 | 2012-10-11 ✅ Patent 9,090,897 granted on 2015-07-28Production of IFN-lambda by conventional dendritic cells
#54 | 2012-07-19MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCNATION OF NEONATES
#55 | 2012-07-05 ✅ Patent 8,470,578 granted on 2013-06-25Purification of vaccinia viruses using hydrophobic interaction chromatography
#56 | 2012-06-07 ✅ Patent 8,435,535 granted on 2013-05-07Fusion proteins of HIV regulatory/accessory proteins
#57 | 2012-06-07 ✅ Patent 8,389,275 granted on 2013-03-05Fusion proteins of HIV regulatory/accessory proteins
#58 | 2012-05-31 ✅ Patent 9,109,233 granted on 2015-08-18Recombinant poxvirus expressing homologous genes inserted
#59 | 2012-05-31GENERATION OF A BROAD T-CELL RESPONSE IN HUMANS AGAINST HIV
#60 | 2012-05-17 ✅ Patent 8,772,023 granted on 2014-07-08Promoters for recombinant viral expression
#61 | 2012-05-03 ✅ Patent 8,808,709 granted on 2014-08-19Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
#62 | 2012-04-05 ✅ Patent 8,435,543 granted on 2013-05-07Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#63 | 2012-02-16 ✅ Patent 8,414,900 granted on 2013-04-09Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#64 | 2012-01-19 ✅ Patent 8,323,661 granted on 2012-12-04Method for generating a stable recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
#65 | 2012-01-19 ✅ Patent 8,613,936 granted on 2013-12-24Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
#66 | 2012-01-19 ✅ Patent 8,309,098 granted on 2012-11-13Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs)
#67 | 2012-01-12 ✅ Patent 8,354,275 granted on 2013-01-15Induction of dendritic cell development with macrophage-colony stimulating factor (M-CSF)
#68 | 2012-01-12 ✅ Patent 8,198,088 granted on 2012-06-12Method for introducing human immunodeficiency virus nucleotide sequences into a cell utilizing modified vaccinia virus Ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)
#69 | 2011-12-22 ✅ Patent 8,415,132 granted on 2013-04-09Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
#70 | 2011-12-15 ✅ Patent 8,163,531 granted on 2012-04-24Purification of vaccinia viruses using hydrophobic interaction chromatography
#71 | 2011-12-15 ✅ Patent 8,197,822 granted on 2012-06-12Method for the production of human immunodeficiency virus (HIV) proteins utilizing modified vaccinia virus ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)
#72 | 2011-12-08 ✅ Patent 8,211,686 granted on 2012-07-03Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
#73 | 2011-10-13 ✅ Patent 8,288,125 granted on 2012-10-16Intergenic regions as insertion sites in the genome of modified vaccinia virus Ankara (MVA)
#74 | 2011-10-06 ✅ Patent 8,309,326 granted on 2012-11-13Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#75 | 2011-09-29 ✅ Patent 8,999,637 granted on 2015-04-07Vector comprising multiple homologous nucleotide sequences
#76 | 2011-09-08 ✅ Patent 8,236,560 granted on 2012-08-07Modified Vaccinia Ankara virus variant and cultivation method
#77 | 2011-09-08 ✅ Patent 8,329,466 granted on 2012-12-11Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
#78 | 2011-07-28 ✅ Patent 8,268,329 granted on 2012-09-18Modified virus variant
#79 | 2011-07-28 ✅ Patent 8,268,325 granted on 2012-09-18Modified Vaccinia Ankara virus variant
#80 | 2011-07-21 ✅ Patent 8,268,327 granted on 2012-09-18Immediate protection against pathogens via MVA
#81 | 2011-06-30 ✅ Patent 8,372,622 granted on 2013-02-12Modified vaccinia virus ankara for the vaccination of neonates
#82 | 2011-06-09 ✅ Patent 8,163,293 granted on 2012-04-24Modified Vaccinia Virus Ankara for the vaccination of neonates
#83 | 2011-01-27 ✅ Patent 8,034,356 granted on 2011-10-11Monoparamunity inducers based on attenuated rabbit myxoma viruses
#84 | 2011-01-20PROMOTERS FOR EXPRESSION IN MODIFIED VACCINIA VIRUS ANKARA
#85 | 2011-01-20 ✅ Patent 8,039,004 granted on 2011-10-18Methods of preparing myxomavirus compositions
#86 | 2011-01-13PROMOTERS FOR EXPRESSION IN MODIFIED VACCINIA VIRUS ANKARA
#87 | 2010-12-16 ✅ Patent 8,142,796 granted on 2012-03-27Monoparamunity inducers based on attenuated rabbit myxomaviruses
#88 | 2010-12-02 ✅ Patent 8,034,354 granted on 2011-10-11Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#89 | 2010-11-04 ✅ Patent 7,964,398 granted on 2011-06-21Modified vaccinia ankara virus variant and cultivation method
#90 | 2010-09-16 ✅ Patent 8,394,385 granted on 2013-03-12Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
#91 | 2010-08-05 ✅ Patent 8,029,800 granted on 2011-10-04Recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
#92 | 2010-07-22 ✅ Patent 8,021,669 granted on 2011-09-20Methods for inducing an immune response in a host comprising administering modified vaccinia virus ankara (MVA) recombinants comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
#93 | 2010-07-01 ✅ Patent 8,445,275 granted on 2013-05-21Induction of dendritic cell development with macrophage-colony stimulating factor (M-CSF)
#94 | 2010-06-03 ✅ Patent 8,815,501 granted on 2014-08-26Flavivirus NS1 subunit vaccine
#95 | 2010-05-27 ✅ Patent 8,268,328 granted on 2012-09-18Immediate protection against pathogens via MVA
#96 | 2010-05-27 ✅ Patent 8,012,738 granted on 2011-09-06Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
#97 | 2010-05-13 ✅ Patent 8,003,364 granted on 2011-08-23Purification of vaccinia viruses using hydrophobic interaction chromatography
#98 | 2010-05-13 ✅ Patent 7,939,086 granted on 2011-05-10Modified Vaccinia Ankara virus variant
#99 | 2010-05-06 ✅ Patent 8,003,363 granted on 2011-08-23Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
#100 | 2010-02-25 ✅ Patent 7,892,533 granted on 2011-02-22Modified vaccinia virus ankara for the vaccination of neonates
Also check out BAVARIAN NORDIC A/S's (Kvistgaard, Denmark) applicant profile with 39 patent applications submitted.
17628 ⎘